| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| D X Brown, M Choudhury, M Evan. Linagliptin as add-on therapy for type 2 diabetes - an overview. Drugs of today (Barcelona, Spain : 1998). vol 48. issue 10. 2012-12-28. PMID:23110260. |
the pathogenesis of type 2 diabetes (t2d) can result in decreased levels of glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), which under normal circumstances increase insulin secretion and suppress glucagon release. |
2012-12-28 |
2023-08-12 |
Not clear |
| T E Adrian, S Gariballa, K A Parekh, S A Thomas, H Saadi, J Al Kaabi, N Nagelkerke, B Gedulin, A A Youn. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia. vol 55. issue 9. 2012-12-18. PMID:22696033. |
we investigated the effects of intrarectal sodium taurocholate on plasma glp-1, pyy, insulin and glucose concentrations, and on food intake of a subsequent meal. |
2012-12-18 |
2023-08-12 |
human |
| Y-S Lee, M-S Park, J-S Choung, S-S Kim, H-H Oh, C-S Choi, S-Y Ha, Y Kang, Y Kim, H-S Ju. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia. vol 55. issue 9. 2012-12-18. PMID:22722451. |
glucagon-like peptide-1 (glp-1) is known to reduce insulin resistance. |
2012-12-18 |
2023-08-12 |
mouse |
| Daisuke Shiraishi, Yukio Fujiwara, Yoshihiro Komohara, Hiroshi Mizuta, Motohiro Takey. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochemical and biophysical research communications. vol 425. issue 2. 2012-12-18. PMID:22842565. |
glp-1 is now used for the treatment of diabetes because of its beneficial role against insulin resistance. |
2012-12-18 |
2023-08-12 |
human |
| Su-fang Liu, Ping Chen, Ji-tian X. [Effects of GLP-1(7-36)NH2 on insulin secretion and the changes of intracellular cAMP and insulin mRNA expression]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology. vol 20. issue 3. 2012-12-07. PMID:21192403. |
[effects of glp-1(7-36)nh2 on insulin secretion and the changes of intracellular camp and insulin mrna expression]. |
2012-12-07 |
2023-08-12 |
Not clear |
| Ruth B S Harris, John W Apolza. Changes in glucose tolerance and leptin responsiveness of rats offered a choice of lard, sucrose, and chow. American journal of physiology. Regulatory, integrative and comparative physiology. vol 302. issue 11. 2012-11-29. PMID:22496363. |
in experiment 2 choice rats were insulin insensitive during an intraperitoneal gtt, but this was corrected in an oral gtt due to glp-1 release. |
2012-11-29 |
2023-08-12 |
rat |
| Rachel E Roberts, Min Zhao, Ben C Whitelaw, John Ramage, Salvador Diaz-Cano, Carel W le Roux, Alberto Quaglia, Guo Cai Huang, Simon J B Aylwi. GLP-1 and glucagon secretion from a pancreatic neuroendocrine tumor causing diabetes and hyperinsulinemic hypoglycemia. The Journal of clinical endocrinology and metabolism. vol 97. issue 9. 2012-11-26. PMID:22774207. |
glucagon-like peptide-1 (glp-1) is a gut peptide that promotes insulin release from pancreatic β-cells and stimulates β-cell hyperplasia. |
2012-11-26 |
2023-08-12 |
Not clear |
| S Sein. Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia. vol 55. issue 8. 2012-11-21. PMID:22555472. |
in addition, a variety of glucose-lowering drugs including sulfonylureas, glinide-derivatives, and incretin-related drugs such as dipeptidyl peptidase iv (dpp-4) inhibitors and glucagon-like peptide 1 (glp-1) receptor agonists are used for glycaemic control by targeting beta cell signalling for improved insulin secretion. |
2012-11-21 |
2023-08-12 |
Not clear |
| Moahad S Dar, William H Chapman, John R Pender, Almond J Drake, Kevin O'Brien, Robert J Tanenberg, G Lynis Dohm, Walter J Porie. GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)? Obesity surgery. vol 22. issue 7. 2012-11-19. PMID:22419108. |
oral meal consumption increases glucagon-like peptide 1 (glp-1) release which maintains euglycemia by increasing insulin secretion. |
2012-11-19 |
2023-08-12 |
Not clear |
| A H Heald, R P Narayanan, D Lowes, E Jarman, E Onyekwelu, Z Qureshi, I Laing, S G Anderso. HOMA-S is associated with greater HbA1c reduction with a GLP-1 analogue in patients with type 2 diabetes. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 120. issue 7. 2012-11-13. PMID:22639398. |
exenatide, a glucagon-like peptide-1 (glp-1) analogue, is an effective glucoregulator for treating overweight individuals, not at target hba1 c. this prospective study aimed to determine whether estimates of beta cell function (homa-b) and insulin sensitivity (homa-s) predict response to exenatide treatment.prospective data on 43 type 2 diabetes patients were collected for up to 2.8 years in uk primary care. |
2012-11-13 |
2023-08-12 |
Not clear |
| A H Heald, R P Narayanan, D Lowes, E Jarman, E Onyekwelu, Z Qureshi, I Laing, S G Anderso. HOMA-S is associated with greater HbA1c reduction with a GLP-1 analogue in patients with type 2 diabetes. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 120. issue 7. 2012-11-13. PMID:22639398. |
determination of insulin sensitivity may assist in guiding outcome expectation in overweight patients treated with glp-1 analogues. |
2012-11-13 |
2023-08-12 |
Not clear |
| Harald S Hansen, Mette M Rosenkilde, Jens J Holst, Thue W Schwart. GPR119 as a fat sensor. Trends in pharmacological sciences. vol 33. issue 7. 2012-11-09. PMID:22560300. |
it is a major target for the development of anti-diabetic drugs that through gpr119 activation may stimulate both insulin and glp-1 release. |
2012-11-09 |
2023-08-12 |
Not clear |
| Dominique Xavier Brown, Marc Evan. Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. Journal of nutrition and metabolism. vol 2012. 2012-11-06. PMID:23125920. |
glp-1 receptor agonists such as liraglutide and exenatide exert an intrinsic biological effect on glp-1 receptors directly stimulating the release of insulin from pancreatic beta cells. |
2012-11-06 |
2023-08-12 |
Not clear |
| M S Fineman, B B Cirincione, D Maggs, M Diaman. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, obesity & metabolism. vol 14. issue 8. 2012-11-05. PMID:22233527. |
glucagon-like peptide-1 (glp-1), a gut-derived hormone secreted in response to nutrients, has several glucose and weight regulating actions including enhancement of glucose-stimulated insulin secretion, suppression of glucagon secretion, slowing of gastric emptying and reduction in food intake. |
2012-11-05 |
2023-08-12 |
Not clear |
| J Boubaker, D Val-Laillet, S Guérin, C-H Malber. Brain processing of duodenal and portal glucose sensing. Journal of neuroendocrinology. vol 24. issue 8. 2012-11-05. PMID:22487360. |
the present study aimed to compare the respective influence of these sensing pathways on the eating patterns; plasma concentrations of glucose, insulin and glucagon-like peptide-1 (glp-1); and brain activity in juvenile pigs. |
2012-11-05 |
2023-08-12 |
Not clear |
| J Boubaker, D Val-Laillet, S Guérin, C-H Malber. Brain processing of duodenal and portal glucose sensing. Journal of neuroendocrinology. vol 24. issue 8. 2012-11-05. PMID:22487360. |
in experiment 2, glucose, insulin and glp-1 plasma concentrations were measured during 2 h after duodenal or portal glucose infusions in four anaesthetised animals. |
2012-11-05 |
2023-08-12 |
Not clear |
| Hans Juergen Woerle, Lucianno Carneiro, Ayman Derani, Burkhard Göke, Jörg Schirr. The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes. vol 61. issue 9. 2012-11-05. PMID:22721966. |
in order to quantify the role of incretins in first- and second-phase insulin secretion (isr) in type 2 diabetes mellitus (t2dm), a double-blind, randomized study with 12 t2dm subjects and 12 healthy subjects (hs) was conducted using the hyperglycemic clamp technique together with duodenal nutrition perfusion and intravenous infusion of the glucagon-like peptide 1 (glp-1) receptor antagonist exendin(9-39). |
2012-11-05 |
2023-08-12 |
human |
| R C Mollard, B L Luhovyy, S Panahi, M Nunez, A Hanley, G H Anderso. Regular consumption of pulses for 8 weeks reduces metabolic syndrome risk factors in overweight and obese adults. The British journal of nutrition. vol 108 Suppl 1. 2012-11-05. PMID:22916807. |
blood glucose, insulin, c-peptide, glucagon-like peptide-1 (glp-1) and ghrelin were measured after a 75 g oral glucose load at weeks 1 and 8. |
2012-11-05 |
2023-08-12 |
human |
| Carolyn F Deaco. Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes? Diabetes. vol 61. issue 9. 2012-11-05. PMID:22923648. |
is endogenous glp-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes? |
2012-11-05 |
2023-08-12 |
Not clear |
| Kazutaka Aoki, Hiroshi Kamiyama, Kouichiro Yoshimura, Makoto Shibuya, Kiyomi Masuda, Yasuo Terauch. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta diabetologica. vol 49. issue 3. 2012-10-29. PMID:21898126. |
we measured the plasma glucose, serum insulin and glucagon, plasma active glp-1, and total glucose-dependent insulinotropic polypeptide levels before breakfast, at 120 min after breakfast, before lunch, and 60 and 120 min after lunch in patients with diabetes who are receiving sitagliptin. |
2012-10-29 |
2023-08-12 |
human |